Research Roundup: What we’re reading this week
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
GHTC member TB Alliance and partners announced this week that they have advanced the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global Phase III clinical trial. The drug regimen—called PaMZ—is expected to reduce the cost of multi-drug resistant TB treatment by over 90 percent in some countries.
This week in Seattle, the Bill & Melinda Gates Foundation convened the Global Health Product Development Forum—where more than 500 people will discuss how funders, researchers, nongovernmental organizations, and the private sector can work together to accelerate the development and delivery of life-saving products.
The United Kingdom has launched a five-year, £375 million fund to support science and innovation partnerships with researchers in low- and middle-income countries. The new fund will support joint research projects, student and researcher fellowships, capacity building, and translational research.
The Kaiser Family Foundation has created an infographic that shows global health funding’s share of the US federal budget. The infographic highlights the recent flattening of US funding for global health and the major areas US global health funding goes to.